finanzen.net
18.06.2019 01:51
Bewerten
(0)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV

NEW YORK, June 17, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc ("Nabriva" or the "Company") (NASDAQ:  NBRV) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-04713, is on behalf of a class consisting of all persons and entities who purchased or otherwise acquired Nabriva securities between November 1, 2018 and April 30, 2019, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased Nabriva securities during the class period, you have until July 8, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Nabriva is a biopharmaceutical company that purports to develop novel anti-infective agents to treat serious infections. One of the Company's product candidates is CONTEPO, an epoxide antibiotic developed by Zavante Therapeutics ("Zavante"), which the Company acquired in July 2018.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company's manufacturers failed to meet good manufacturing practices; (ii) these manufacturers would be subject to inspections by the FDA in connection with the Company's NDA; (iii) as a result of the manufacturing deficiencies, the Company's NDA for CONTEPO was unlikely to be approved by the FDA; and (iv) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On April 30, 2019, the Company revealed that the U.S. Food and Drug Administration ("FDA") would not approve its New Drug Application ("NDA") for CONTEPO due to "issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers."

On this news, the Company's share price fell $0.82 per share, or over 27%, to close at $2.17 per share on May 1, 2019, on unusually high trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert--pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-nabriva-therapeutics-plc-of-class-action-lawsuit-and-upcoming-deadline--nbrv-300869922.html

SOURCE Pomerantz LLP

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Die 5 beliebtesten Top-Rankings

Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
In diesen Berufen bekommt man das niedrigste Gehalt
Welche Branchen man besser meiden sollte.
mehr Top Rankings

Umfrage

Verteidigungsministerin Annegret Kramp-Karrenbauer will eine deutliche Steigerung der deutschen Rüstungsausgaben. Unterstützen Sie diese Forderung?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Daimler AG710000
Deutsche Bank AG514000
Infineon AG623100
Amazon906866
BASFBASF11
NEL ASAA0B733
Microsoft Corp.870747
BayerBAY001
Apple Inc.865985
Volkswagen (VW) AG Vz.766403
Continental AG543900
CommerzbankCBK100
TeslaA1CX3T
EVOTEC SE566480